Association of RASSF1A Promoter Methylation with Lung Cancer Risk: a Meta-analysis

  • Huang, Ying-Ze (Lab of Molecular Genetics of Aging and Tumor, Medical Faculty, Kunming University of Science and Technology) ;
  • Wu, Wei (Lab of Molecular Genetics of Aging and Tumor, Medical Faculty, Kunming University of Science and Technology) ;
  • Wu, Kun (Lab of Molecular Genetics of Aging and Tumor, Medical Faculty, Kunming University of Science and Technology) ;
  • Xu, Xiao-Ning (Lab of Molecular Genetics of Aging and Tumor, Medical Faculty, Kunming University of Science and Technology) ;
  • Tang, Wen-Ru (Lab of Molecular Genetics of Aging and Tumor, Medical Faculty, Kunming University of Science and Technology)
  • Published : 2015.01.06


RASSF1A, regarded as a candidate tumor suppressor, is frequently silenced and inactivated by methylation of its promoter region in many human tumors. However, the association between RASSF1A promoter methylation and lung cancer risk remains unclear. To provide a more reliable estimate we conducted a meta-analysis of cohort studies to evaluate the potential role of RASSF1A promoter methylation in lung carcinogenesis. Relevant studies were identified by searches of PubMed, Web of Science, ProQest and Medline databases using the following key words: 'lung cancer or lung neoplasm or lung carcinoma', 'RASSF1A methylation' or 'RASSF1A hypermethylation'. According to the selection standard, 15 articles were identified and analysised by STATA 12.0 software. Combined odds ratio (OR) and 95% confidence interval (CI) were used to assess the strength of the association between RASSF1A promoter methylation and lung cancer risk. A chi-square-based Q test and sensitivity analyses were performed to test between-study heterogeneity and the contributions of single studies to the final results, respectively. Funnel plots were carried out to evaluate publication bias. Overall, a significant relationship between RASSF1A promoter methylation and lung cancer risk (OR, 16.12; 95%CI, 11.40-22.81; p<0.001) with no between-study heterogeneity. In subgroup analyses, increased risk of RASSF1A methylation in cases than controls was found for the NSCLC group (OR, 13.66, 95%CI, 9.529-19.57) and in the SCLC group (OR, 314.85, 95%CI, 48.93-2026.2).


RASSF1A;lung cancer;methylation;NSCLC and SCLC


Supported by : Higher Education of China


  1. Amin KS, Banerjee PP (2012). The cellular functions of RASSF1A and its inactivation in prostate cancer. J Carcinog, 11, 3.
  2. Baylin SB (2005). DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol, 2, 4-11.
  3. Brock MV HC, Ota-Machida E, Han Y, et al (2008). DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med, 13, 1118-28.
  4. Burbee DG, Forgacs E, Zochbauer-Muller S, et al (2001). Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst, 93, 691-9.
  5. Chen H, Suzuki M, Nakamura Y, et al (2006). Aberrant methylation of RASGRF2 and RASSF1A in human non-small cell lung cancer. Oncol Rep, 15, 1281-5.
  6. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88.
  7. Dickersin K, Berlin JA (1992). Meta-analysis: state-of-thescience. Epidemiol Rev, 14, 154-76.
  8. Egger M, Davey Smith G, Schneider M, Minder C. (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34
  9. Fischer JR, Ohnmacht U, Rieger N, et al (2007). Prognostic significance of RASSF1A promoter methylation on survival of non-small cell lung cancer patients treated with gemcitabine. Lung Cancer, 56, 115-23.
  10. Grote HJ, Schmiemann V, Geddert H, et al (2006). Methylation of RAS association domain family protein 1A as a biomarker of lung cancer. Cancer Cytopathology, 108, 129-34.
  11. Helmbold P, Lahtz C, Herpel E, et al (2009). Frequent hypermethylation of RASSF1A tumour suppressor gene promoter and presence of Merkel cell polyomavirus in small cell lung cancer. Eur J Cancer, 45, 2207-11.
  12. Hesson LB, Cooper WN, Latif F (2007). The role of RASSF1A methylation in cancer. Dis Markers, 23, 73-87.
  13. Agathanggelou A, Bieche I, Ahmed-Choudhury J, et al (2003). Identification of novel gene expression targets for the Ras association domain family 1 (RASSF1A) tumor suppressor gene in non-small cell lung cancer and neuroblastoma. Cancer Res, 63, 5344-51.
  14. Agathanggelou A, Honorio S, Macartney DP, et al (2001). Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene, 20, 1509-18.
  15. Hirsch FR, Merrick DT, Franklin WA (2002). Role of biomarkers for early detection of lung cancer and chemoprevention. Eur Respir J, 19, 1151-8.
  16. Honorio S, Agathanggelou A, Schuermann M, et al (2003). Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients. Oncogene, 22, 147-50.
  17. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.
  18. Joseph Lau M, John PA Ioannidis, MD, Christopher H Schmid (1998). Summing up evidence: one answer is not always enough. The Lancet, 351, 123-7.
  19. Lee SM, Lee WK, Kim DS, et al (2012). Quantitative promoter hypermethylation analysis of RASSF1A in lung cancer: comparison with methylation-specific PCR technique and clinical significance. Mol Med Rep, 5, 239-44.
  20. Li W, Deng J, Jiang P, et al (2012). Methylation of the RASSF1A and RARbeta genes as a candidate biomarker for lung cancer. Exp Ther Med, 3, 1067-71.
  21. Li W, Deng J, Tang JX (2014). Combined effects methylation of FHIT, RASSF1A and RARbeta genes on non-small cell lung cancer in the Chinese population. Asian Pac J Cancer Prev, 15, 5233-7.
  22. Lin Q, Geng J, Ma K, et al (2009). RASSF1A, APC, ESR1, ABCB1 and HOXC9, but not p16INK4A, DAPK1, PTEN and MT1G genes were frequently methylated in the stage I non-small cell lung cancer in China. J Cancer Res Clin Oncol, 135, 1675-84.
  23. Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
  24. Niklinski J, Niklinska W, Chyczewski L, et al (2005). Prognostic value of aberrant promoter methylation of DAPK and RASSF1A genes in early stage of non-small cell lung cancer (NSCLC). Lung Cancer, 49, 293-S.
  25. Safar AM, Spencer H, 3rd, Su X, et al (2005). Methylation profiling of archived non-small cell lung cancer: a promising prognostic system. Clin Cancer Res, 11, 4400-5.
  26. Wang J, Lee JJ, Wang L, et al (2004). Value of p16INK4a and RASSF1A promoter hypermethylation in prognosis of patients with resectable non-small cell lung cancer. Clin Cancer Res, 10, 6119-25.
  27. Wang Y, Yu Z, Wang T, et al (2007). Identification of epigenetic aberrant promoter methylation of RASSF1A in serum DNA and its clinicopathological significance in lung cancer. Lung Cancer, 56, 289-94.
  28. WIL BWSaCP (D2014). World Cancer Report 2014. World Health Organization.
  29. Yanagawa N, Tamura G, Oizumi H, et al (2007). Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers. Lung Cancer, 58, 131-8.
  30. Zhai X, Li SJ (2014). Methylation of RASSF1A and CDH13 genes in individualized chemotherapy for patients with non-small cell lung cancer. Asian Pac J Cancer Prev, 15, 4925-8.
  31. Zhang H, Zhang S, Zhang Z, et al (2010). Prognostic value of methylation status of RASSF1A gene as an independent factor of non-small cell lung cancer. Zhongguo Fei Ai Za Zhi, 13, 311-6 (in Chinese).

Cited by

  1. Clinical utility of RASSF1A methylation in human malignancies vol.113, pp.3, 2015,
  2. STAT3 methylation in white blood cells as a novel sensitive biomarker for the toxic effect of low-dose benzene exposure vol.5, pp.3, 2016,
  3. The Indirect Efficacy Comparison of DNA Methylation in Sputum for Early Screening and Auxiliary Detection of Lung Cancer: A Meta-Analysis vol.14, pp.7, 2017,